IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·
← Ticker index
RVTY
Ticker

RVTY

Congressional Trades
63
by 5 members
Ticker disclosure brief

Congressional disclosure records for RVTY

A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.

Latest receipt
Ro Khanna
BUY · 2026-06-30
Largest range
$15K – $50K
Gilbert Cisneros
Longest observed gap
58d
Lisa McClain
Highest 30d vs SPY
27.9%
Gilbert Cisneros
Purchase rows
44
70%
Sale rows
19
30%
Disclosed midpoint
$602K
range estimate
Unique Traders
5
members
Disclosure timing method

Observed filing gaps are not notice-date findings

The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.

Party Breakdown

Democrats53 · 84%
Republicans10 · 16%

Federal awards

all →
  • 2026-06-16$17K
    Department of Health and Human Services
    THE SECTION ON MEDICINAL CHEMISTRY DEVELOPS NEW MOLECULAR ENTITIES WITH IMPLACTION IN IMPROVING HEALTH AND TREATMENT FOR VARIOUS METABOLIC DIESEASES. TO ASSESS THE TRANSLATIONAL POTENTIAL OF NOVEL MOLECULAR ENTITIES, WHICH WOULD ALLOW US TO MAKE DECI
  • 2026-06-15$27K
    Department of Health and Human Services
    NIDA: SUPPLY: UNIFILTER-96 CELL HARVESTER 55: N/A
  • 2026-06-08$19K
    Department of Health and Human Services
    CMT-ASD. CELLOMETER ASCEND AUTOMATED CELL COUNTER. REFERENCE QUOTE Q-135389
  • 2026-04-29$770K
    Department of Health and Human Services
    COMPLETE SERVICE AGREEMENT FOR TWO (2) OPERETTA CLS HIGH-CONTENT IMAGING SYSTEMS , SIX (6) OPERA PHENIX CONFOCAL MICROSCOPY SYSTEMS, AND ASSOCIATED INTEGRATED EQUIPMENT
  • 2026-04-16$117K
    Department of Health and Human Services
    BASE AND 1 OPTION YEAR SERVICE AND MAINTENANCE OF REVVITY OPERA PHENIX PLUS SYSTEM MICROSCOPE
  • 2026-04-08$51K
    Department of Veterans Affairs
    REPAIR OF IVIS CT SYSTEM
  • 2026-03-06$36K
    Department of Health and Human Services
    MAINTENANCE AGREEMENT FOR EQUIPMENT MAINTENANCE AND CUSTOMER SUPPORT.
  • 2026-02-17$108K
    Department of Health and Human Services
    REVVITY SCICLONE/ZEPHYR PMA

Lobbying filings

all →
  • 2026-07-13$40K
    REVVITY INC.
    Diagnostic test reimbursement and policies Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 H.R. 2810, Family Cord Blood Banking Act S. 4612 SCREEN for Type 1 Diabetes Act Newborn Screening Amendment to NDAA
  • 2026-04-23$35K
    REVVITY INC.
    Diagnostic test reimbursement and policies Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 H.R. 2810, Family Cord Blood Banking Act Support for Genetic Screening Proposals related to pandemic preparedness
  • 2026-01-09$30K
    REVVITY INC.
    Diagnostic test reimbursement and policies Genomic sequencing Proposals related to newborn screening HR 4709 - Newborn Screening Saves Lives Act Reauthorization Act of 2025 Proposals related to pandemic preparedness FDA Medical Device Product policies H.R. 2810, Family Cord Blood Banking Act Medical Device & Pharmaceutical Adjacent Tariffs
  • 2025-10-02$30K
    REVVITY INC.
    Diagnostic test reimbursement and policies Genomic sequencing T-Cell Immune Response Testing Proposals related to newborn screening Newborn Screening Saves Lives Act Proposals related to pandemic preparedness FDA Medical Device Product policies H.R. 2810, Family Cord Blood Banking Act Medical Device & Pharmaceutical Adjacent Tariffs Medical Device & Pharmaceutical Adjacent Tariff
  • 2025-04-24$30K
    REVVITY INC.
    Diagnostic test reimbursement and policies Genomic sequencing T-Cell Immune Response Testing Proposals related to newborn screening Proposals related to pandemic preparedness FDA Medical Device Product policies H.R. 2810, Family Cord Blood Banking Act Medical Device & Pharmaceutical Adjacent Tariff
  • 2025-04-24$0
    REVVITY INC.
    SARS-CoV-2 Testing, including RT-PCR Testing, Rapid Antigen Testing, Genomic Sequencing, and T Cell Immune Response Testing, and related reimbursement and policies. Newborn Screening Saves Lives Reauthorization Act; FDA Medical Device Product policies; The Family Cord Blood Banking Act and cord blood tissue and collection and storage payment policies; Pandemic preparedness and prevention policies; Medical Device & Pharmaceutical Adjacent Tariffs. SARS-CoV-2 Testing, including RT-PCR Testing, Rapid Antigen Testing, Genomic Sequencing, and T Cell Immune Response Testing, and related reimbursement and policies. Newborn Screening Saves Lives Reauthorization Act; FDA Medical Device Product policies; The Family Cord Blood Banking Act and cord blood tissue and collection and storage payment policies; Pandemic preparedness and prevention policies; Medical Device & Pharmaceutical Adjacent Tariffs. SARS-CoV-2 Testing, including RT-PCR Testing, Rapid Antigen Testing, Genomic Sequencing, and T
  • 2025-04-07$70K
    REVVITY INC. (FORMERLY PERKINELMER INC.)
    Diagnostic test reimbursement and policies; Proposals related to newborn screening; Proposals related to pandemic preparedness; H.R. 8882, To amend the Internal Revenue Code of 1986 to treat amounts paid for private umbilical cord blood, or umbilical cord tissue, banking services as medical care expenses
Loading trade analytics…

All Disclosed Trades

Page 1 · 25 of 63 shown
DateMemberActionAmountObserved GapReceipt
2026-06-30DRo KhannaBUY$1K – $15K6dreceipt →
2026-05-15DRo KhannaBUY$1K – $15K25dreceipt →
2026-05-04DGilbert CisnerosBUY$15K – $50K36dreceipt →
2026-05-04DGilbert CisnerosBUY$15K – $50K35dreceipt →
2026-04-13DRo KhannaBUY$1K – $15K28dreceipt →
2026-04-13DRo KhannaBUY$1K – $15K28dreceipt →
2026-05-01DGilbert CisnerosBUY$1K – $15K10dreceipt →
2026-05-01DGilbert CisnerosBUY$1K – $15K10dreceipt →
2026-05-01DGilbert CisnerosBUY$1K – $15K7dreceipt →
2026-02-05DRo KhannaSELL$1K – $15K32dreceipt →
2026-02-05DRo KhannaSELL$1K – $15K32dreceipt →
2026-01-29DRo KhannaBUY$1K – $15K8dreceipt →
2026-01-29DRo KhannaBUY$1K – $15K8dreceipt →
2025-09-12DGilbert CisnerosBUY$1K – $15K31dreceipt →
2025-09-12DGilbert CisnerosBUY$1K – $15K28dreceipt →
2025-09-12DGilbert CisnerosBUY$1K – $15K28dreceipt →
2025-09-29DRo KhannaBUY$1K – $15K4dreceipt →
2025-09-29DRo KhannaBUY$1K – $15K4dreceipt →
2025-08-13DGilbert CisnerosBUY$1K – $15K33dreceipt →
2025-08-13DGilbert CisnerosBUY$1K – $15K30dreceipt →
2025-08-13DGilbert CisnerosBUY$1K – $15K30dreceipt →
2025-08-26DRo KhannaSELL$1K – $15K14dreceipt →
2025-08-04DRo KhannaSELL$1K – $15K36dreceipt →
2025-08-26DRo KhannaSELL$1K – $15K14dreceipt →
2025-08-04DRo KhannaSELL$1K – $15K36dreceipt →

“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.